Pictet Asset Management
TRML

Pictet Asset Management’s Tourmaline Bio TRML Stock Holding History

Pictet Asset Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-682,129
Closed -$10.9M – 2086
2025
Q2 		$10.9M Buy
682,129
+262,246
+62% +$4.25M 0.01% 636
2025
Q1 		$6.39M Hold
419,883
– – 0.01% 758
2024
Q4 		$8.52M Buy
419,883
+172,743
+70% +$4.35M 0.01% 707
2024
Q3 		$6.35M Buy
+247,140
New +$4.12M 0.01% 759

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Pictet Asset Management's TRML Position: Q3 2025 in Review

Pictet Asset Management sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 682,129 shares — an estimated $10.9M sold.

Pictet Asset Management first reported a position in TRML in Q3 2024 and held it in 4 quarters. The position peaked at $10.9M in Q2 2025. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Pictet Asset Management reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Pictet Asset Management sold 682,129 Tourmaline Bio shares in Q3 2025, an estimated $10.9M.
  • Pictet Asset Management first reported a position in Tourmaline Bio in Q3 2024 and held it in 4 quarters.
  • Pictet Asset Management's Tourmaline Bio position peaked at $10.9M in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Pictet Asset Management's 13F filing for Q3 2025, filed 18 Nov 2025.